2004
DOI: 10.1016/j.ijcard.2003.06.013
|View full text |Cite
|
Sign up to set email alerts
|

Ischemic heart disease in women and the role of hormone therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
7
1
2

Year Published

2004
2004
2019
2019

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 19 publications
(10 citation statements)
references
References 191 publications
(126 reference statements)
0
7
1
2
Order By: Relevance
“…This is in contrast to recent randomized clinical trials, which have suggested that a combination of equine estrogens plus progestin do not confer cardiac protection and indeed may increase the risk of CAD [27].…”
Section: Introductioncontrasting
confidence: 92%
See 2 more Smart Citations
“…This is in contrast to recent randomized clinical trials, which have suggested that a combination of equine estrogens plus progestin do not confer cardiac protection and indeed may increase the risk of CAD [27].…”
Section: Introductioncontrasting
confidence: 92%
“…Numerous clinical observational, animal and cellular studies reported beneficial effects of estrogen on cardiovascular disease risk [27]. This is in contrast to recent randomized clinical trials, which have suggested that a combination of equine estrogens plus progestin do not confer cardiac protection and indeed may increase the risk of CAD [27].…”
Section: Introductionmentioning
confidence: 82%
See 1 more Smart Citation
“…Moreover, the impact of diabetes mellitus and obesity on causing CVD is more severe in women (Reza, Reinhart, & Movahed, 2004). Another risk factor that is specific to women is attributed to ovarian disorders after menopause (Stone, 1996) (He, Sengupta, Velkoff, & DeBarros, 2005).…”
mentioning
confidence: 99%
“…Despite "optimal" medical therapy, a large fraction of patients continue to present with angina and myocardial ischemia [1]. It is recommended that treatment strategies should include modifying risk factors such as diet, weight loss, regular exercise, smoking cessation and adequate control of hypertension, diabetes, and hyperlipidemia [2]. Diltiazem (DTZ), losartan, amlodipine and dipyridamole are clinically proven effective cardiovascular agents for ischemic heart disease and have considerable potential for treatment and prevention of atherosclerosis and stroke [3][4][5].…”
Section: Introductionmentioning
confidence: 99%